Oxford Biomedica appoint new CEO
Life sciences firm Oxford Biomedica have appointed a new CEO.
The gene and cell therapy firm announced the appointment of Dr Frank Mathias as CEO to share holders this week.
Dr Mathias will take up the role and a position on the board from March 2023. In doing so he replaces Dr Roch Doliveux who was named Non-Executive Chairman of the Group in June 2020.
Since 2016 Dr Mathias served as CEO of Rentschler Biopharma SE. In 2019 he was awarded the title of “EY Entrepreneur of the Year” in Germany. Prior to Rentschler, Dr Mathias was CEO of publicly listed Medigene AG, an immuno-oncology company focusing on the development of T-cell-based cancer therapies.
Dr Roch Doliveux will remain as Interim CEO of Oxford Biomedica until March 2023, at which point Dr Mathias will fully take over the role of CEO and Dr Doliveux will resume the role of Non-Executive Chair.
Read more - Covid vaccine wind-down hits revenue and profits at Oxford Biomedica
Commenting on the appointment, Dr Roch Doliveux, Chair and Interim CEO of Oxford Biomedica, said: “Frank is an outstanding patient centric leader with impressive experience from a top-end CDMO as well as from innovative biopharma companies. He has a strong track record of delivering growth and driving performance and innovation which are core strengths required to implement our strategy of becoming an innovative global viral vector leader.”
Dr Frank Mathias, said: “Oxford Biomedica is a world-leader in the innovative development and manufacture of viral vectors for life-saving cell and gene therapies, demonstrated by the ever-expanding customer base of now more than 20 programmes across all vector types.
"With momentum continuing to build across the business, I am excited by the potential for the Company. I look forward to joining Oxford Biomedica and working with all of the staff, the Board and partners to execute the strategy and deliver the next phase of growth as a world-class, innovation-led CDMO helping to improve the lives of patients.”
Read more - Oxford Biomedica to sell and leaseback its facility for £60 million
